Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in the immunobiology and treatment of inflammatory myopathies.

Literature DB >> 17688838

Advances in the immunobiology and treatment of inflammatory myopathies.

Abstract

The clinical spectrum and immunopathogenesis of inflammatory myopathies are summarized with an update on possible triggering factors, cell degeneration, and emerging new therapies.

Entities: Disease

Mesh：

Substances：

Year: 2007 PMID： 17688838 DOI： 10.1007/s11926-007-0047-5

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.592

85 in total

1. Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors: Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal: Muscle Nerve Date: 2007-01 Impact factor: 3.217

Review 2. Polymyositis, dermatomyositis and inclusion-body myositis.

Authors: M C Dalakas
Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245

3. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

Authors: A M Emslie-Smith; K Arahata; A G Engel
Journal: Hum Pathol Date: 1989-03 Impact factor: 3.466

4. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis.

Authors: Dalia Dimitri; Olivier Benveniste; Odile Dubourg; Thierry Maisonobe; Bruno Eymard; Zahir Amoura; Laetitia Jean; Kiet Tiev; Jean-Charles Piette; David Klatzmann; Serge Herson; Olivier Boyer
Journal: Brain Date: 2006-02-02 Impact factor: 13.501

5. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

Authors: Raghavan Raju; Marinos C Dalakas
Journal: Brain Date: 2005-04-27 Impact factor: 13.501

6. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis.

Authors: I Ferrer; M Carmona; R Blanco; D Moreno; B Torrejón-Escribano; M Olivé
Journal: Brain Pathol Date: 2005-04 Impact factor: 6.508

7. Polymyositis in patients infected with human T-cell leukemia virus type I: the role of the virus in the cause of the disease.

Authors: M Leon-Monzon; I Illa; M C Dalakas
Journal: Ann Neurol Date: 1994-10 Impact factor: 10.422

8. Polymyositis associated with AIDS retrovirus.

Authors: M C Dalakas; G H Pezeshkpour; M Gravell; J L Sever
Journal: JAMA Date: 1986-11-07 Impact factor: 56.272

9. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis.

Authors: Simona Ozden; Madeleine Cochet; Jacqueline Mikol; Antonio Teixeira; Antoine Gessain; Claudine Pique
Journal: J Virol Date: 2004-10 Impact factor: 5.103

10. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle.

Authors: Gaetano Vattemi; W King Engel; Janis McFerrin; Valerie Askanas
Journal: Am J Pathol Date: 2004-01 Impact factor: 4.307

3 in total

1. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation.

Authors: Maurizio Vitadello; Andrea Doria; Elena Tarricone; Anna Ghirardello; Luisa Gorza
Journal: Arthritis Res Ther Date: 2010-03-24 Impact factor: 5.156

Review 2. Clinical applications of intravenous immunoglobulins in neurology.

Authors: R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330

3. In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized.

Authors: Chiara Terracciano; Anna Nogalska; W King Engel; Slawomir Wojcik; Valerie Askanas
Journal: Free Radic Biol Med Date: 2008-06-14 Impact factor: 7.376

3 in total